Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent

  • Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers
  • The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda
  • The company has received patent protection for the REQORSA-Keytruda drug combination in the U.S., Japan, Australia, Russia, Mexico, and China, meaning the company has secured exclusivity in many of the largest markets
  • The granted patents, three Fast Track Designations, and positive preclinical and clinical data are poised to help the company accelerate its clinical development of REQORSA in its various development programs

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company on a mission to develop life-changing therapies for patients with cancer and diabetes, recently received a patent in China – Genprex China Patent No: 201780076886.X – from the China National Intellectual Property Administration. The granted patent broadly covers the use of the company’s drug candidate REQORSAI immunogene therapy in combination with PD-1 antibodies, such as KeytrI(R), to treat cancers (https://ibn.fm/AD3iX).

The REQORSA gene therapy in combination with Keytruda is the subject of the company’s ongoing Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). In this trial, the company is enrolling and treating patients with advanced, metastatic NSCLC whose disease progressed after treatment with Keytruda. The first patient was dosed in this study in April of last year (https://ibn.fm/7lqLl).

Against the backdrop of the ongoing study, Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex, described how the patent granted in China provides Genprex with important additional protection for the use of the REQORSA and PD-1 antibody combination.

“Now with the latest patent grant in China, we have secured exclusivity for the use of this drug combination for the treatment of cancer in some of the most important markets in the world.  The company already has received patent protection in the U.S., Australia, Mexico, Japan and Russia.  This patent protection prevents others from using this drug combination to treat cancer in these jurisdictions,” Gallagher explains.

REQORSA uses the company’s non-viral ONCOPREX(R) Nanoparticle Delivery System, a systemic gene therapy platform for cancer. The system encapsulates within lipid nanoparticles a plasmid that expresses the TUSC2 tumor suppressor gene, creating the REQORSA drug product. The company then intravenously administers the encapsulated plasmid, which is then taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in these cells (https://ibn.fm/I80mh).

According to the company, “REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death (apoptosis) in cancer cells, and modulates the immune response against cancer cells.” This lead product candidate is initially being developed in combination with prominent cancer drugs Tagrisso(R), Keytruda(R), and Tecentriq(R) to treat NSCLC and small cell lung cancer (“SCLC”) (https://ibn.fm/gf7tO).

Having received three separate Fast Track Designations from the U.S. Food and Drug Administration (“FDA”) for its combination therapies with Tagrisso, Keytruda and Tecentriq, the company looks forward to accelerating the clinical development of REQORSA and potentially providing new treatments for patients. Moreover, Genprex’s growing patent portfolio is expected to boost these clinical development efforts.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050